(Q31980098)

English

Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

1 reference

based on heuristic

inferred from title

author name string

S R Tollin

1

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

publication date

1 December 2000

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Journal of Endocrinological Investigation

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

765-770

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Neuroleptic-induced hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1007%2FBF03345068

21 January 2018

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects

1 reference

https://api.crossref.org/works/10.1007%2FBF03345068

21 January 2018

Prolactogenic effects of risperidone in male patients--a preliminary study

1 reference

https://api.crossref.org/works/10.1007%2FBF03345068

21 January 2018

Hyperprolactinemia and male sexual dysfunction

1 reference

https://api.crossref.org/works/10.1007%2FBF03345068

21 January 2018

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

1 reference

https://api.crossref.org/works/10.1007%2FBF03345068

21 January 2018

Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups

1 reference

https://api.crossref.org/works/10.1007%2FBF03345068

21 January 2018

Prolactin levels and adverse events in patients treated with risperidone

1 reference

https://api.crossref.org/works/10.1007%2FBF03345068

21 January 2018

Drug therapy: Bromocriptine

1 reference

https://api.crossref.org/works/10.1007%2FBF03345068

21 January 2018

Brom-ergocryptine in the Treatment of Phenothiazine-Induced Galactorrhoea

1 reference

https://api.crossref.org/works/10.1007%2FBF03345068

21 January 2018

Decreased bone mineral density in medicated psychiatric patients

1 reference

https://api.crossref.org/works/10.1007%2FBF03345068

21 January 2018

Risperidone-induced galactorrhea associated with a prolactin elevation

1 reference

https://pubmed.ncbi.nlm.nih.gov/11194712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Implications of not treating hyperprolactinemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/11194712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Osteoporosis associated with neuroleptic treatment. A case report

1 reference

https://pubmed.ncbi.nlm.nih.gov/11194712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risperidone and associated amenorrhea: a report of 5 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/11194712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Effect of Amantadine on Prolactin Levels and Galactorrhea on Neuroleptic-Treated Patients*

1 reference

https://pubmed.ncbi.nlm.nih.gov/11194712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response

1 reference

https://pubmed.ncbi.nlm.nih.gov/11194712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amantadine in the treatment of neuroendocrine side effects of neuroleptics.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11194712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolactin levels in premenopausal women treated with risperidone compared with those of women treated with typical neuroleptics

1 reference

https://pubmed.ncbi.nlm.nih.gov/11194712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Herbal medicine (Shakuyaku-kanzo-to) in the treatment of risperidone-induced amenorrhea

1 reference

https://pubmed.ncbi.nlm.nih.gov/11194712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risperidone-induced prolactin elevations in premenopausal women with schizophrenia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11194712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of psychotropic-induced hyperprolactinemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/11194712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone

1 reference

https://pubmed.ncbi.nlm.nih.gov/11194712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bromocriptine in the treatment of haloperidol-induced galactorrhea

1 reference

https://pubmed.ncbi.nlm.nih.gov/11194712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bromocriptine in the treatment of galactorrhea caused by haloperidol: a case study

1 reference

https://pubmed.ncbi.nlm.nih.gov/11194712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical experience with risperidone.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11194712

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF03345068

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Dimensions Publication ID

0 references

release_xvrdogllqnbh7fjsuonumwwxpm

1 reference

https://api.fatcat.wiki/v0/release/xvrdogllqnbh7fjsuonumwwxpm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31980098&oldid=2175451322"